Desmopressin Nasal Spray for Hemophilia A and Type I von Willebrand Disease
Authors: S.V. Seremetis
Journal: Annals of Internal Medicine (1997)

Letters1 May 1997Desmopressin Nasal Spray for Hemophilia A and Type I von Willebrand DiseaseS.V. Seremetis, MD and L.M. Aledort, MDS.V. Seremetis, MDMount Sinai Medical Center, New York, NY 10029Search for more papers by this author and L.M. Aledort, MDMount Sinai Medical Center, New York, NY 10029Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-9-199705010-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Desmopressin (1-deamino-8-D-arginine vasopressin), administered intravenously or subcutaneously, has an established role in the treatment of patients with mild to moderate hemophilia A and type I von Willebrand disease [1-3]; it substitutes for plasma-derived coagulation products and avoids the risk for infection with bloodborne viruses. We evaluated the long-term safety and efficacy of home care use of high-concentration intranasal desmopressin in 20 patients with mild hemophilia A or type I von Willebrand disease, in whom coagulation variables were previously shown to respond to this therapy.Despite promising short-term studies, no data other than one preliminary report [4] have ...References1. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet. 1977; 1:1869-72. Google Scholar2. Warrier I, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia and von Willebrand disease. J Pediatr. 1983; 102:228-33. Google Scholar3. De La Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin. Ann Intern Med. 1985; 103:6-14. Google Scholar4. Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut. 1990; 60:187-91. Google Scholar5. Seremetis S, Aledort LM. Nasal spray desmopressin (DDAVP)-experience in home care and surgical prophylaxis. Preliminary report [Abstract]. Blood. 1991; 78(Suppl):275A. Google Scholar Author, Article, and Disclosure InformationAuthors: S.V. Seremetis, MD; L.M. Aledort, MDAffiliations: Mount Sinai Medical Center, New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDesmopressin as a hemostatic and blood sparing agent in bleeding disordersThe use of desmopressin in mild hemophilia ALaboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunctionPerioperative Management of the Patient with Hematologic DisordersHigh-dose DDAVP intranasal spray (Stimate ® ) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia AFemales with von Willebrand disease: 72 years as the silent majorityDDAVP Use During PregnancyAntidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers 1 May 1997Volume 126, Issue 9Page: 744-745KeywordsHemophiliaHemophilia AHemorrhageHemostaticsInfectious diseasesProphylaxisSafetyTrauma surgeryVasopressinvon Willebrand disease ePublished: 15 August 2000 Issue Published: 1 May 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...